Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 22, 2023
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
Wed, June 21, 2023
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
[ Wed, Jun 21st 2023
] - WOPRAI
Charles Duncan Reiterated (XENE) at Buy and Held Target at $58 on, Jun 21st, 2023
Charles Duncan of Cantor Fitzgerald, Reiterated "Xenon Pharmaceuticals Inc." (XENE) at Buy and Held Target at $58 on, Jun 21st, 2023.
Charles has made no other calls on XENE in the last 4 months.
There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Charles's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Charles
- Yatin Suneja of "Guggenheim" Reiterated at Strong Buy and Held Target at $49 on, Thursday, June 15th, 2023
- Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $47 on, Wednesday, May 10th, 2023
- Tessa Romero of "JP Morgan" Maintained at Buy with Increased Target to $55 on, Tuesday, April 25th, 2023
- Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $50 on, Friday, April 21st, 2023
- Brian Abrahams of "RBC Capital" Reiterated at Buy and Held Target at $51 on, Wednesday, March 22nd, 2023
